Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 127,199 | 129,688 | 164,859 | 114,449 | 81,732 |
| Cost of Goods | 1,950 | 2,554 | 1,585 | 1,521 | 4,679 |
| Gross Profit | 125,249 | 127,134 | 163,274 | 112,928 | 77,053 |
| Operating Expenses | 163,114 | 160,119 | 138,928 | 126,099 | 120,406 |
| Operating Income | -36,915 | -32,431 | 24,931 | -12,650 | -42,674 |
| Interest Expense | 2,300 | 2,294 | 2,751 | 2,846 | 2,857 |
| Other Income | 2,493 | 13,660 | 3,534 | 2,761 | 4,344 |
| Pre-tax Income | -36,722 | -21,065 | 25,714 | -12,735 | -41,187 |
| Income Tax | -120 | 921 | 8 | 20 | 39 |
| Net Income Continuous | -36,602 | -21,986 | 25,706 | -12,755 | -41,226 |
| Net Income Discontinuous | -500 | N/A | 0 | 0 | 0 |
| Net Income | $-37,102 | $2,729 | $25,706 | $-12,755 | $-41,226 |
| EPS Basic Total Ops | -0.40 | 0.03 | 0.29 | -0.14 | -0.47 |
| EPS Basic Continuous Ops | -0.40 | -0.25 | 0.29 | -0.14 | -0.47 |
| EPS Basic Discontinuous Ops | -0.01 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.40 | 0.04 | 0.28 | -0.14 | -0.47 |
| EPS Diluted Continuous Ops | -0.40 | -0.21 | 0.25 | -0.14 | -0.47 |
| EPS Diluted Discontinuous Ops | -0.01 | N/A | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | N/A | 0.03 | 0.28 | -0.14 | -0.47 |
| EBITDA(a) | $-11,703 | $-17,090 | $40,719 | $1,366 | $-29,872 |